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1. Introduction 
Congenital heart defects (CHD) affect approximately 1% of live births. Some of them are 
associated with a significant morbidity and mortality and congenital heart diseases remain 
the first cause of death among infants in North America and Europe (Bruneau, 2008).  
The major causes in CHD are thought to be chromosomal aberrations or mutations in genes 
regulating cardiac development during embryogenesis (Pierpont et al., 2007). However, 
from the epidemiological data, it seems that the environment can have a small “teratogenic” 
effect (Jenkins et al., 2007). For example, some substances (e.g. prenatal exposure to 
angiotensin converting-enzyme inhibitors, alcohol abuse and Rubella virus) can alter the 
function of certain genes during embryogenesis (Bruneau, 2008; Cooper et al., 2006). 
Though, these epidemiological studies have mostly suggested risk rather than pinpointing 
the underlying disease mechanisms. 
During heart development complex interactions, among cells originating from different cell 
lineages, occur.  In normal human heart development, a four-chambered heart ensure 
normal cardiac physiology with a right heart serving to the low-pressure pulmonary system 
and a left heart to the high pressure body circulation (Srivastava, 2004). A malformed 
cardiac growth results in abnormal hemodynamic characteristics because of volume or 
pressure overload leading to an adaptation process of the heart.  
The completion of the Human Genome Project heralded the beginning of a new medical 
science era. The available genomic data will markedly improve our ability to diagnose and 
treat a great number of diseases including heart disease. Examining an individual’s genomic 
profile or “molecular fingerprint” in a disease context now might help us to understand 
disease mechanisms and could found a new health care tailored to individual patient that take 
into account the predicted disease course and response to therapies of that patient. There’s 
now a real opportunity to replace invasive diagnostic tests with genomic tests that can be 
carried out with no or little risk or stress to the patients (Bell, 2004; Collins et al., 2003).  
The objective of this chapter is to provide an overview of gene expression profiling 
technology and the state of genomic research in congenital heart diseases, specifically with 
regard to the use of microarray approach.  
2. Clinical overview of congenital heart diseases  
Congenital heart defects, affecting most heart’s parts (Figure 1), can be classified into three 
categories: cyanotic heart disease, left-sided obstruction defects and septation defects 
(Bruneau, 2008). In cyanotic heart disease, the mixing of oxygenated and deoxygenated 
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blood results in the blue appearance of affected infants. Defects contributing to this 
condition include transposition of the great arteries (TGA), tetralogy of Fallot (TOF), 
tricuspid atresia, pulmonary atresia, Ebstein's anomaly of the tricuspid valve, double outlet 
right ventricle (DORV), persistent truncus arteriosus (PTA) and total anomalous pulmonary 
venous connection. The second main type of congenital heart disease, left-sided obstructive 
lesions, includes hypoplastic left heart syndrome (HLHS), mitral stenosis, aortic stenosis, 
aortic coarctation and interrupted aortic arch (IAA). The third type of congenital heart 
disease, septation defects, can affect septation of the atria (atrial septation defects, ASDs), 
septation of the ventricles (ventricular septal defects, VSDs) or formation of structures in the 
central part of the heart (atrioventricular septal defects, AVSDs). Other types of congenital 
defect that do not fit into the above three main categories are bicuspid aortic valve (BAV) 
and patent ductus arteriosus (PDA). 
 
 
Fig. 1. Congenital heart defects. Diagram of heart illustrating the structures that are affected 
by congenital heart diseases. AC, aortic coarctation; AS, aortic stenosis; ASD, atrial septal 
defect; AVSD, atrioventricular septal defect; BAV, bicuspid aortic valve; DORV, double 
outlet right ventricle; Ebstein's, Ebstein's anomaly of the tricuspid valve; HLHS, hypoplastic 
left heart syndrome; HRHS, hypoplastic right heart; IAA, interrupted aortic arch; MA, 
mitral atresia; MS, mitral stenosis; PDA, patent ductus arteriosus; PS, pulmonary artery 
stenosis; PTA, persistent truncus arteriosus; TA, tricuspid atresia; TAPVR, total anomalous 
pulmonary venous return; TGA, transposition of the great arteries; TOF, tetralogy of Fallot; 
VSD, ventricular septal defect. 
Depending on the severity of the congenital heart disease, mortality and morbidity varies 
but can be serious. The number of surgeries needed to correct many of the anatomical 
defects can weaken the affected children and considerably compromise their quality of life.  
Congenital heart surgery has made tremendous gains over the past 10 years; however, 
recovery and outcome statistics continue to point out the need for improvements in this 
increasingly younger patient population. Paediatric patients undergoing cardiac surgery 
continue to need mechanical assist devices, as well as prolonged inotropic support or an 
open chest despite a technically perfect repair. Moreover, perioperative myocardial damage 
with low cardiac output remains the most common cause of morbidity and death after 
repair of congenital lesions (Hammon, 1995). It is therefore essential to improve our 
understanding of the genetic mechanisms and pathways associated with the different 
congenital heart conditions and their response to the surgical stress of ischaemia and 
reperfusion injury and cardiopulmonary bypass.  
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3. Gene expression profiling 
In the pre-human genome sequencing era, the possibility to identify a relevant set of 
causative genes for multigenic diseases such as cardiomyopathies was limited. Classical 
genetic approaches were developed to find single loci or genes with the power to cause 
Mendelian disorders. In this case, disorders can result from a single base change in the 
deoxyribonucleic acid (DNA) that leads to significant alteration in protein abundance or 
function. However in disorders resulting from multiple gene variants that collectively 
contribute to an individual’s multigenic defect, new genomics approaches are needed. With 
the arrival of such genomics technologies, genes microarrays approach has emerged as a 
real opportunity allowing the performance of gene expression analysis of disease-relevant 
tissues. If DNA defines the inherent genetic make up of a person, it is the transcription of the 
DNA into RNA (that could be translated into protein) that integrates the dynamic 
interaction of an individual with the environment. Consequently, microarrays provide us 
with an opportunity to measure mRNA abundance that correlate with a particular disease 
state, clinical outcome, or therapeutic response, giving us an unprecedented opportunity to 
investigate the genomic contribution to cardiovascular diseases (Cook and Rosenzweig, 
2002; Goldsmith and Dhanasekaran, 2004; Napoli et al., 2003). 
3.1 Microarray technology 
Expression profiling is the study of the expression level changes of large numbers of genes 
simultaneously. The concept of microarray technology is simple: specific DNA sequences, 
called “probes,” are selected to “target” genes of interest. Microarrays refer to solid 
substrates of glass, plastic, or silicon containing hundreds or thousands of microscopic spots 
of DNA (Figure 2). Each of the DNA spots, apposed to the solid material, contains hundreds 
to thousands of identical probes. Each probe has a sequence of nucleotide bases that is 
complementary and unique to a single gene. Because of the technology’s advances, it is 
common to use microarrays carrying the entire complement of the human genome in 
today’s microarray experiments. 
 
 
Fig. 2. Schematic of a microarray experiment. cDNA, complementary deoxyribonucleic acid; 
cRNA, complementary ribonucleic acid. 
In a typical microarray experiment, RNA is extracted from a tissue or sample of interest. The 
small part of the RNA population that represents the transcribed genes, mRNA, is 
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amplified, and fluorescent tags are attached to each molecule. The labelled mRNA is then 
incubated with the microarray allowing the tagged mRNA molecules to hybridize to the 
probes containing the specific complementary sequence of genes. Complementary mRNAs 
bind to probes on the array during hybridization. The microarray is then washed and placed 
in a scanner where a laser is directed onto each spot, causing the tags to fluoresce. The 
resulting fluorescence intensity is proportional to the number of tagged RNAs that have 
hybridized to the probes in each spot. The measured intensity represents the expression 
level or activity of that gene. Consequently, an expression profile can be generated for a 
particular tissue at different stages of health or disease. 
The identified gene signatures are useful because they represent an initial step in 
identifying disease-associated genes, or “candidate genes”. Furthermore, they represent a 
disease biomarker. The genes that comprise the genomic signature are associated with 
disease susceptibility or a particular treatment outcome. These candidate genes might 
substantially improve our understanding of disease biology and subsequently lead to 
identification of potential targets for new treatment strategies (King et al., 2005). The other 
great potential for transcriptomic information is to use the gene signatures as a disease 
biomarker. Gene expression data could offer a remarkable detailed patient phenotype that 
could be used to correctly classify patient populations as to their disease risk or response 
to therapies. In both cases, genomic data represent a means to distinguish between 
patients who are otherwise alike by classical clinical variables (Cook and Rosenzweig, 
2002; Goldsmith and Dhanasekaran, 2004; Napoli et al., 2003). This is still a work in 
progress in cardiovascular medical research. But we can look to the cancer research field 
to see where the future lies. 
3.2 Standardization 
Experimental conditions can affect microarray technology in a way that leads to considerable 
variability and low reproducibility of the results. To make it possible to compare data obtained 
from different laboratories, efforts have been directed towards the definition of standards in 
gene expression studies (Stoeckert et al., 2002). These standards cover all experimental steps in 
microarray investigations and extend from sample selection and experimental design to the 
functional classification of altered genes. Complex statistical algorithms are increasingly used 
for data modeling and expression change identification. Additionally, comparative approaches 
have been proposed to evaluate the performance of various algorithms on gene expression 
data (Bolstad et al., 2003; Cope et al., 2004; Irizarry et al., 2006).  
3.3 Experimental design 
Microarray experiments should always be replicated. There are two types of replications: 
biological replication, where multiple homogeneous samples are used on multiple arrays, 
and technical replication, where RNA from the same sample is used on multiple arrays. If 
biological replication allows the estimation of both measurements and biological variability, 
technical replication allows only the estimation of measurement variability. Ideally, 
experimental design should include both types. Although there is no agreement about the 
optimum number of biological replicates, a minimum of 5 for each group is generally 
considered as a minimum. 
RNA pooling is another crucial issue. Pooling RNA from biological replicates can reduce 
variability among arrays. Pooling can be necessary for samples of limited quantity. However 
the analysis of one single pool can be misleading because it prevents the estimation of 
biological variability and the presence of outlier samples which could change the results. An 
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alternative approach is the multiple pooling, in which for example 25 samples can be divided 
into 5 pools of 5 samples, and each pool may be used on distinct microarray platforms. Many 
studies have used pooling. In contrast not many have used multiple pooling. 
3.4 Data normalization 
Because of variability of microarray data, each array must be brought into the same scale as 
others in order to compare 2 or more arrays. This normalization, performed by removing 
systematic variation between the arrays and rendering different experiments comparable, 
remains an issue that is not yet fully resolved. Although, many of the early microarray 
studies in the literature ignored this issue, a statistically rigorous approach is needed.  
Early software allowed for array-to-array comparisons by using a scaling factor to normalize 
gene expression patterns across arrays. However, in general, these algorithms assume that 
intensity differences between arrays are linearly related (Schadt et al., 2000). Such linear 
relationship often does not hold true. An example of this approach is the global method that 
consists in re-scaling each chip data set by its total intensity.   
A more advanced normalization approaches have been developed. The invariant set method 
is based on the assumption that there is a subset of unchanged genes between any two 
samples compared by microarray analysis so that their fluorescence values can be used to 
normalize the entire expression data set (Li and Wong, 2001). The LOcally WEighted 
Scatterplot Smoothing (LOWESS) is a widely used technique based on non-linear regression 
(Yang et al., 2002). The quantile normalization uses non-parametric procedure to normalize 
each chip (Bolstad et al., 2003). However, one of the best statistically robust normalization 
methods is the “Robust Multiarray Average” technique (RMA) (Irizarry et al., 2003). This 
method corrects microarray data for local background; it normalizes data on normal 
distribution and uses a linear model to estimate expression values on a log scale. It has been 
demonstrated that RMA performs better than other normalization technologies for 
Affymetrix data (Irizarry et al., 2003). 
3.5 Identification of differentially expressed genes 
The fold-change (FC) was the first used method to identify significantly deregulated genes. 
Although this simple technique can be efficient and effective for focusing on expanding sets 
of differentially expressed sequences, such an analysis does not take advantage of the full 
potential of genome-scale experiments to enhance our comprehension of cellular biology 
that would be provided by an inclusive analysis of the entire repertoire of transcripts in a 
cell as it goes through a biological process. Additionally, FC is now considered an 
inadequate statistical test since it does not incorporate variance and offers no associated 
levels of confidence. To compare groups of data, the parametric t-test and the analysis of 
variance (ANOVA) are more robust and commonly used. However, due to the small sample 
size in a microarray experiment, parametric methods are not recommended and should be 
substituted with a non-parametric moderated test.  
Statistical analysis of microarray data faces an important challenge because testing the 
expression level of tens of thousands of transcripts (multiple testing) may produce hundreds 
of false positive. Therefore, multiple test corrections should be applied. Since the Bonferroni 
approach is too conservative in the case of large number of tests, a good alternative is the 
use of false discovery rate (FDR) (Benjamini and Hochberg, 1995). FDR, defined as the 
expected number of false positive in a list of genes, is at the present widely used for gene 
expression data analysis. 
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3.6 Data organization and presentation 
In order to detect and extract patterns within microarray data, statistical algorithms can be 
applied. The basic assumption of many expression profiling’ investigations is that knowing 
where and when a gene is expressed provides information about the function of the gene. 
Therefore, organizing genes on the basis of similarities in their expression profiles is a 
crucial starting point in the analysis (Bassett et al., 1999). However, similarity of gene 
expression profile does not guaranty similarity of function or mechanistic pathway, and it 
may occur entirely by chance. Nonetheless, clustering genes on the basis of their expression 
patterns is well accepted (Eisen et al., 1998). Typically, cluster analysis is applied when more 
than 3 experiments’ data sets are available. It is generally performed in a two-way method 
(cluster analysis on genes and samples). Nowadays, cluster analysis is one of the most 
popular statistical techniques applied to large-scale microarray data. 
Another method called discriminant analysis, that is different from the descriptive cluster 
analysis, belongs to the group of predictive algorithms. At the start of the analysis, the 
samples are divided into two or more classes. Then based on a training set, where the 
scientist knows a priori the source class of each sample, the algorithms predict the class of 
new samples using its expression profile. 
The different cluster techniques can usefully organize tables of gene expression values. 
However the resulting organized but still large collection of numbers remains hard to 
assimilate. Therefore, powerful data visualization methods and tools have been developed. 
These approaches present clustering results in simple graphical displays such as dendrograms 
(Figure 3). Dendrograms represent relationships among genes by a tree whose branch lengths 
reflect the degree of mathematically defined similarity in expression between the genes (Alon 
et al., 1999). It is possible to make visual assimilation more intuitive by combining clustering 
methods with representation of each data point with a color that quantitatively and 
qualitatively reflects the original experimental observations (Eisen et al., 1998). 
 
 
Fig. 3. Hierarchical clustering of two groups of three samples. Hierarchical groups are 
displayed on the heat map and dendrogram at the left side of the heat map. 
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3.7 Network and pathway analysis 
More recently, new analysis methods have been developed to help interpreting microarray 
data within biological and physiopathological contexts. These approaches are gene 
interaction network analysis and pathway analysis. In gene interaction network analysis 
(Figure 4), automated text mining software is usually used to scan the scientific literature to 
identify gene-gene interactions. A human expert can improve the quality of these gene 
relationships. When a list of differentially expressed genes is presented to the program, a 
search system returns relevant interaction networks. In pathway analysis, the pathways, 
made-up of gene-gene interactions, are accepted by the scientific community and entered 
into the system by human experts. Because of the higher confidence, needed before a set of 
interacting genes is called a pathway, these databases are smaller but more accurate. It is 
however possible to identify new pathways based on gene network interactions if the 
interactions can be validated and accepted by the peer review community. Many 
bioinformatics programs are now available enabling in-depth analysis of any interrelated 
biological data, finding common regulators and associating pathway components with like-
behaving biological entities and processes. 
 
 
Fig. 4. Example of interaction network analysis (Ghorbel et al., 2010). The association 
between the network entities were based on available PubMed citations.  
3.8 Data archiving 
Successful interpretation of expression profiling investigations is likely to be dependent on 
the integration of experimental data with external information resources. Since the amount 
of data from multiple studies involving multiple cell types and tissues from multiple 
research groups is fast growing, data archiving is becoming an important issue. It is ideal if 
all gene expression data would be deposited in the public domain and are freely accessible. 
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Such endeavour would require a user-friendly and powerful database system and 
standardization of correction and normalization procedures to allow comparison of data 
sets from various projects (Granjeaud et al., 1999). Public data repositories have been 
developed at the European Bioinformatics Institute (ArrayExpress) and the National Center 
for Biotechnology Information (Gene Expression Omnibus), institutions that pursue these 
internationally recognized standards. Several scientific journals now request submission of 
microarray data into databases as a prerequisite for manuscript publication.  
4. Exploring transcriptomic alterations in congenital heart diseases 
The refinement of the human genome sequence and its associated annotation will soon have 
a great impact on the diagnosis and treatment of cardiovascular diseases when this 
information is coupled to the application of new technologies such as DNA microarrays. 
The latter provides a genomic approach to explore the genetic markers and molecular 
mechanisms leading to congenital heart disease and heart failure. 
The first genome-wide gene expression study of congenitally malformed hearts in humans 
attempted to identify genes associated with dysdevelopment as well as genes involved in 
adaptation processes of the heart (Kaynak et al., 2003). The authors of this study, examined 
and compared genes dysregulated in defined congenitally malformed hearts with the 
molecular response to pressure overload leading to hypertrophy and the chamber-specific 
cardiac molecular portrait (Kaynak et al., 2003). By comparing the gene expression in atria 
and ventricle, this study found diverse previously unknown chamber-specific genes for 
muscle contraction, extracellular components, cell growth and differentiation, and energy 
metabolism (Kaynak et al., 2003). This is in addition to well-known chamber-specific genes, 
like atrial and ventricular myosin light chains. The comparison of Tetralogy of Fallot (TOF) 
and Right ventricular Hypertrophy (RVH), showed a distinct molecular portraits of TOF 
and RVH with genes of various functional classes (Kaynak et al., 2003) even though the right 
ventricular hypertrophy is part of TOF. Beside genes involved in cell cycle, a characteristic 
feature of the TOF signature is the upregulation of ribosomal proteins (Kaynak et al., 2003). 
Whereas a hypertrophy-specific gene expression pattern of genes mainly involved in stress 
response, cell proliferation, and metabolism was observed in RVH (Kaynak et al., 2003). In 
addition, to obtain a molecular portrait that is not influenced by biomechanical adaptation 
processes, RA samples of patients with ventricular septal defect (VSD), intact tricuspid 
valve, and normal RA pressure were studied (Kaynak et al., 2003). A VSD-specific molecular 
signature dominated by downregulated genes with respect to the other RA samples was 
shown (Kaynak et al., 2003). A thorough literature study of downregulated genes in VSD 
revealed that a major part is involved in cell proliferation and differentiation during 
embryogenesis as well as apoptosis (Kaynak et al., 2003). This investigation indicated 
distinct gene expression profiles associated with tetralogy of Fallot, ventricular septal defect, 
and right ventricular hypertrophy (Kaynak et al., 2003). Furthermore, the study design 
allowed the suggestion that alterations associated with primary genetic abnormalities can be 
distinguished from those associated with the adaptive response of the heart to the 
malformation (right ventricular pressure overload hypertrophy) (Kaynak et al., 2003).  
The evidence for the developmentally regulated capacity of the immature heart to generate 
an adaptive response to reduced oxygen availability, although compelling, is derived 
largely from acute experimental interventions in animal models. Further, the reductionist 
approach of these studies, which typically address a single target, fails to capture the global 
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complexity of the response. Nevertheless, the general observation that the human neonatal 
heart copes well with dramatic degrees of hypoxia and hypertrophy is in accordance with 
these experimental findings. To determine the molecular basis of this putatively adaptive 
response, Konstantinov et al. conducted microarray-based differential gene expression 
profiling on tissue samples acquired in patients of varying ages undergoing repair of right 
ventricular (RV) obstructive heart lesions, including TOF and focusing on potential age-
related differences (Konstantinov et al., 2004). Their findings seem to confirm the existence 
of a protective reprogramming response that is most evident in the neonatal myocardium 
and is subject to the hemodynamic and metabolic stress imposed by structural congenital 
heart disease (Konstantinov et al., 2004). Indeed this study showed that neonatal 
myocardium has a unique pattern of gene expression dominated by genes with 
cardioprotective, antihypertrophic and antiproliferative properties reflecting a stress-
induced protective program (Konstantinov et al., 2004). 
Another investigation examined the differential gene expression profile during RVH in the 
developing heart with TOF congenital defect (Sharma et al., 2006). Using high-density DNA 
microarray, the authors showed that more than 200 myocardial genes are up- or 
downregulated in patients with TOF (Sharma et al., 2006). Among other genes, the 
expression of ECM proteins, such as collagens and fibronectin, was predominantly elevated, 
whereas MMP and TIMP expression either remained unchanged or decreased in TOF 
patients (Sharma et al., 2006). These results indicate for the myocardial fibrosis that may 
account for diminished function in patients with TOF (Sharma et al., 2006). They also 
provide further evidence that myocardial architecture in patients with TOF depict a complex 
and differential gene expression pattern with drastically increased expression level of ECM 
proteins (collagen Iα and III and fibronectin) mRNA and the VEGF/VEGF-R system 
(Sharma et al., 2006). The authors concluded that this up-regulation of genes involved in 
ECM homeostasis is associated with RVH and diminished cardiac function in TOF patients. 
Furthermore, the VEGF/VEGF-receptor (R) system could play an important role in 
enhanced myocardial angiogenesis that could be stunted due to limited vascular 
remodelling (Sharma et al., 2006). 
In contrast to the previous investigation examining gene expression changes in cyanotic 
TOF in comparison to normal hearts (Sharma et al., 2006), we recently determined the global 
gene expression profiles associated with chronic hypoxia by comparing gene expression of 
cyanotic and acyanotic patients with TOF (Ghorbel et al., 2010). Our data showed that, 
overall, the transcriptional profile in the cyanotic group was characterized by increased 
expression level of genes with literature-validated apoptosis and 
growth/morphogenesis/remodeling properties. It also showed decreased expression levels 
of genes with cardiac function, cell survival, and cytoprotective properties (Ghorbel et al., 
2010). The molecular signatures identified suggest a reprogramming response in the 
cyanotic myocardium activated by the chronic hypoxia imposed by the structural congenital 
heart disease (Ghorbel et al., 2010). The difference between the adaptive and injury-related 
responses would dictate the overall fate of heart cells. 
In addition to investigating the gene expression profiling of the myocardium in response to 
congenital heart defect, other studies focused on gene expression alterations in response to 
surgery. One of these studies examined the gene expression profiles during intra-operative 
myocardial ischemia-reperfusion in corrective cardiac surgery of ventricular septal defect 
(Arab et al., 2007). It described the sequential changes in gene expression in the human 
ventricle during surgically imposed ischemia-reperfusion. The annotation of several genes 
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exhibiting differential expression suggested that the elicited transcriptional response in this 
context is compensatory and adaptive. In silico functional clustering of several genes 
comprising this response revealed dominant up-regulation of transcripts encoding elements 
of pro-hypertrophic cellular growth factor pathways, involving multiple levels of 
regulation, including receptors, cognate signaling kinases, and programmatically linked 
transcription factors. The majority of genes up-regulated in response to cardioplegic arrest 
have literature-confirmed cytoprotective properties, including several that have been 
previously validated as endogenous mediators of ischemic preconditioning. This study 
provided evidence that myocardial ischemic stress associated with repair of VSD induces a 
net protective transcriptional response (Arab et al., 2007). It showed that reversible 
myocardial ischemia-reperfusion during cardiac surgery is associated with an immediate 
genomic response that predicts a net cardioprotective phenotype (Arab et al., 2007). 
The molecular signatures identified with microarray technology can be interpreted as either 
mechanistically relevant to the congenital heart disease pathogenesis or as markers of 
disease progression. We believe that this approach can also be used to identify endogenous 
patterns of gene profiles that are activated in response to the primary disease-causing 
pathway and have the effect of generating a counteracting and highly adaptive pattern of 
gene activation, which serves to suppress aberrant disease-related molecular pathways.  
5. Conclusion 
Overall the information collected by gene expression profiling will help our understanding 
of disease mechanisms and provide insights useful for improving contemporary clinical 
treatment and prognosis of patients with congenital heart defects. 
Congenital heart disease genomic research is still in its early stages with regard to the 
translation of studies’ findings into clinical settings. However, inspection of other medical 
areas shows the potential of genomic medicine and where congenital heart medicine will be, 
possibly within the next few years. Microarrays are already being used in other fields to 
help clinicians better risk-stratify patients in addition to predict therapeutic responses and 
direct clinical and surgical decision making. Although considerable challenges remain, 
congenital heart disease genomic medicine promises to improve patient care and lower 
health care costs. 
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